BALTIMORE (Stockpickr) -- Put down the 10-K filings and the stock screeners. It's time to take a break from the traditional methods of generating investment ideas. Instead, let the crowd do it for you.

>>5 Stocks Poised for Breakouts

From hedge funds to individual investors, scores of market participants are turning to social media to figure out which stocks are worth watching. It's a concept that's known as "crowdsourcing," and it uses the masses to identify emerging trends in the market.

Crowdsourcing has long been a popular tool for the advertising industry, but it also makes a lot of sense as an investment tool. After all, the market is completely driven by the supply and demand, so it can be valuable to see what names are trending among the crowd.

While some fund managers are already trying to leverage social media resources like Twitter to find algorithmic trading opportunities, for most investors, crowdsourcing works best as a starting point for investors who want a starting point in their analysis. Today, we'll leverage the power of the crowd to take a look at some of the most active stocks on the market today.

>>5 Rocket Stocks Worth Buying Now

These "most active" names are the most heavily-traded names on the market -- and often, uber-active names have some sort of a technical or fundamental catalyst driving investors' attention on shares. And when there's a big catalyst, there's often a trading opportunity.

Without further ado, here's a look at today's stocks.

MannKind


Nearest Resistance: $5.25

Nearest Support: N/A

Catalyst: FDA Afrezza Panel

MannKind (MNKD) is off more than 16% this afternoon thanks to news that the firm's Afrezza diabetes product will be facing an FDA panel tomorrow over safety concerns for patients with lung disease. There's a lot on the line with tomorrow's independent panel, and this stock's price action reflects that ramped-up risk profile.

Shares had been bouncing higher in an uptrend for the last several months, but Friday's drop broke the trend. From here, lower levels look like the high-probability outcome for shares of MNKD. The huge event risk over tomorrow's panel makes MNDK difficult to trade without huge risk exposure -- there's more money to be made by waiting for the results to come out, then jumping on the trend.

Teva Pharmaceuticals


Nearest Resistance: N/A

Nearest Support: $51

Catalyst: Supreme Court Appeal

Shares of $49 billion drug maker Teva Pharmaceuticals (TEVA) are up 4.25% this afternoon on news that the Supreme Court will hear its appeal for generic patent infringement on its multiple sclerosis drug Copaxone. If TEVA is successful, it'll stave off competition from cheaper Copaxone generics that were projected to come to market as soon as May.

Technically speaking, TEVA's price action looks buyable today. Shares are breaking out of an ascending triangle pattern, pushing through to new highs on hopes that SCOTUS will block generic drug makers from stepping in on Copaxone.

TEVA continues to be a stellar relative strength name. If it holds $51 in today's session, there's a renewed buy signal in this stock.

MGM Resorts International


Nearest Resistance: $28.75

Nearest Support: $25

Catalyst: Technical Setup

Casino operator MGM Resorts International (MGM) is rallying 4% this afternoon, after getting oversold in March. MGM was another momentum name leading into this rally, so it's no surprise that it's one of the stocks that's bouncing hard today.

What might be more surprising, though, is the technical picture when you zoom out of this chart: In the long term, MGM is showing signs of a top. The breakdown signal comes on a move through $25. While shares are likely to continue higher before a move lower, investors who own MGM should watch that $25 level closely. Sell on the first sign of a breakdown below support.

To see these stocks in action, check out the at Most-Active Stocks portfolio on Stockpickr.



-- Written by Jonas Elmerraji in Baltimore.


RELATED LINKS:







Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Jonas Elmerraji, CMT, is a senior market analyst at Agora Financial in Baltimore and a contributor to

TheStreet. Before that, he managed a portfolio of stocks for an investment advisory returned 15% in 2008. He has been featured in Forbes , Investor's Business Daily, and on CNBC.com. Jonas holds a degree in financial economics from UMBC and the Chartered Market Technician designation.

Follow Jonas on Twitter @JonasElmerraji